Final Program

TUESDAY • MAY 17 287
P521 Altered Toll-Like Receptor 4 and Histone Deacetylase 2
Expression in CFBE41o- Cells Regulates Hemeoxygenase I Via
Nuclear Factor Erythroid 2-Related Factor 2/S.V. Garapati, P.
Mahavadi, M. Henke, A. Guenther, S.P. Chillappagari, Giessen,
Germany, p.A5560
P522
P523
P524
P525
P526
P527
P528
Facilitator:
P529
P530
P531
P532
P533
Increased TGFb1 Alters Cellular Glutathione and Oxidant
Stress in Neonatal Alveolar Macrophage with CFTR
Mutation/T.W. Gauthier, X.D. Ping, L.A.S. Brown, Atlanta, GA,
p.A5563
Qualitative and Quantitative Changes of Gel Forming Mucins
and Exosomes in Response to Infection and Inflammation in
the Airways/B. Batson, M. Arifuzzaman, P. Haridass, H. Dang, P.
Mieczkowski, C. Ribeiro, L. Abdullah, M. Kesimer, Chapel Hill, NC,
p.A5565
2-O, 3-O Desulfated Heparin Blocks High Mobility Group Box1
Release from Macrophages by Inhibition of P300
Acetyltransferase Activity/S. Zheng, A. Kummarapurugu, D.K.
Afosah, N.V. Sankaranarayanan, R. Boothello, Y. Jin, U.R. Desai,
T. Kennedy, J.A. Voynow, Richmond, VA, p.A5566
IL1R1 Regulates MUC5B Production and Inflammatory
Responses in the Airway Epithelium/G. Chen, W.K. O’Neal, Y.
Deng, D. Yu, L. Jones, C. Ribeiro, S.H. Randell, R.C. Boucher,
Chapel Hill, NC, p.A5559
Repeated Aerosol Challenge with CFTRinh-172 and Human
Neutrophil Elastase Results in Prolonged Dysfunction of Airway
Mucus Transport and Loss of b-Adrenergic Responsiveness in
Sheep/W.M. Abraham, J.R. Sabater, D. McClain, R.W. Ball, T.
Ahmed, Miami Beach, FL, p.A5569
High-Dose Ibuprofen Dampens Inflammatory Signaling Via
Microtubule Structure and Dynamics in Cystic Fibrosis Epithelial
Cells/S.M. Rymut, C.U. Cotton, T.J. Kelley, Cleveland, OH, p.A5575
How to Effectively Degrade Neutrophil Extracellular Traps
(NETs) by Airway Nucleases/N. Palaniyar, D.N. Douda, C. Licht,
L. Yip, Toronto, Canada, p.A5577
B.T. Kopp, MD, Columbus, OH
Sustained Effectiveness of Ivacaftor Therapy in Three Sisters
with S549N CFTR/A.R. Strang, K. Peeke, A. Shenoy, A. Chidekel,
Wilmington, DE, p.A5583
Trends in Cystic Fibrosis Hospital Admissions in Ireland: A
National Review/K.N. McCarthy, Co Westmeath, Ireland, p.A5582
Potentiator Therapy Modifies Inflammatory Induced Neutrophil
Activation in Patients with Cystic Fibrosis/M. White, B. Alfawaz,
F. Gargoum, C. McCarthy, E.M. O’Brien, N.G. McElvaney, E.
Reeves, Dublin, Ireland, p.A5584
Characterization of Ivacaftor and Lumacaftor Using BioMAP®
Profiling - Implications for Cystic Fibrosis/S. Velichko, E. Berg,
A. Folias, D. Bassoni, A. O’Mahony, South San Francisco, CA,
p.A5585
Improved Homogeneity of Particle Deposition Following
Ivacaftor Treatment in Cystic Fibrosis/W.D. Bennett, K.L.
Zeman, B.L. Laube, J. Wu, P.J. Mogayzel, S.H. Donaldson, Chapel
Hill, NC, p.A5586
P534
P535
Facilitator:
P536
P537
P538
P539
P540
P541
P542
Facilitator:
P543
P544
P545
Acute and Long Term Effects of Ivacaftor on Air Trapping in
Adults with Cystic Fibrosis and the G551D Mutation/R.J. Adam,
J.D. Dodd, K.B. Hisert, B. Grogan, J.L. Launspach, C.G. Gallagher,
J. Sieren, E.A. Hoffman, M. Welsh, P.K. Singh, E.F. McKone, D.A.
Stoltz, Iowa City, IA, p.A5587
Donor Arterial Partial Pressure of Oxygen and Outcomes After
Lung Transplantation in Children with Cystic Fibrosis/D.
Hayes, Jr., D. Tumin, S.D. Reynolds, D. Malleske, J. Tobias, B.T.
Kopp, Columbus, OH, p.A5578
E. Eber, MD, Graz, Austria
Evidence for Reduced Epithelial Cl- Secretion in Primary
Human Nasal Epithelial Cells of Patients with Chronic
Rhinosinusitis/J.J. Salomon, T. Albrecht, H. Scheuermann, I.
Baumann, M.A. Mall, Heidelberg, Germany, p.A5567
c.2768C>A CFTR Is a Disease-Causing Mutation/X. Zhang, J.S.
Hothi, C. Gushue, S. Srinivasan, D.C. Stokes, W. Zhang, Memphis,
TN, p.A5561
FAM13A a New Lung Modifier Gene in Cystic Fibrosis
Regulates Cytoskeletal Dynamics, RhoA and Enhances
TGF-b-induced EMT/L. Guillot, K. Thompson, C. Hodges, L.
Fiette, N. Rousselet, M. Drumm, P.-Y. Boelle, H. Corvol, Paris,
France, p.A5562
The Metabolic Footprint of the Airway Bacterial Community in
Cystic Fibrosis/J.M.C. Sweetnam, D.R. Denner, E.T. Naureckas,
S.R. White, Augusta, GA, p.A5568
Optimization of hMSCs for Therapeutic Impact in Cystic
Fibrosis/T.L. Bonfield, M.T. Sutton, D. Fletcher, R. Van Heeckeren,
D. Lennon, A.I. Caplan, Cleveland, OH, p.A5576
Phenotypic Characterization of Cultured Human Cystic
Fibrosis Airway Smooth Muscle Cells/M. O’Sullivan, A. Panariti,
J. Jang, M. Pyrch, A.-M. Lauzon, J.G. Martin, Montreal, Canada,
p.A5579
CFTR Amplifiers: A New Class of CFTR Modulator that
Complements the Substrate Limitations of Other CF
Therapeutic Modalities/J.P. Miller, L. Drew, O. Green, A. Villella,
B. McEwan, N. Patel, D. Qiu, A. Bhalla, C. Bastos, D. Parks, K.
Giuliano, K. Longo, M. Ivarsson, B. Munoz, P.-S. Lee, H. Mehmet,
M. Haeberlein, Cambridge, MA, p.A5574
D.B. Sanders, MD, MS, Madison, WI
Comparison of Quantitative Airway Measurements by 3 CT
Algorithms in Children with Mild CF Lung Disease/D. Savage,
O. Weinheimer, M.O. Wielputz, T. Ziyeh, C. Tu, B. Newman, T.E.
Robinson, Palo Alto, CA, p.A5588
Pediatric Hyperpolarized 129Xe MR Imaging: Safety and
Tolerability in Healthy Children and Cystic Fibrosis
Patients/L.L. Walkup, R. Thomen, T. Akinyi, K. Ruppert, Z.I.
Cleveland, J.P. Clancy, J.C. Woods, Cincinnati, OH, p.A5589
Comparison of Lung Clearance Index and Quantitative CT Air
Trapping in Infant/Toddler/Preschool Children Vs. School Age
Children with Cystic Fibrosis (CF)/T.E. Robinson, M.L. Goris, C.E.
Milla, T. Kongstad, K. Green, K.G. Nielsen, Palo Alto, CA, p.A5590
TUESDAY MORNING
ATS 2016 • San Francisco